Comparative trial of nafoxidine and ethinyloestradiol in advanced breast cancer: an E.O.R.T.C. study.
- 28 June 1975
- Vol. 2 (5973), 711-713
- https://doi.org/10.1136/bmj.2.5973.711
Abstract
A randomized clinical trial of nafoxidine, a non-steroidal oestrogen antagonist, and ethinyloestradiol in postmenopausal patients with advanced breast cancer produced objective remissions in 31% of 49 women receiving nafoxidine and in 14% of 49 receiving ethinyloestradiol. The differences in remission rates was almost significant (0.05 less than P less than 0.10). Life-threatening complications were more frequent with ethinyloestradiol than with nafoxidine but the latter produced specific toxic reactions on skin and hair that may limit its practical usefulness. Synthetic oestrogen antagonists may occupy a privileged place in the treatment of breast cancer, and other representatives of this new class of compounds should be accurately assessed in randomized clinical trials.Keywords
This publication has 8 references indexed in Scilit:
- The effect of antiestrogens on the nuclear binding of the estrogen receptorSteroids, 1974
- Hormone dependence in breast cancerMetabolism, 1974
- Estrogen receptor · anti-estrogen complex: Atypical binding by uterine nuclei and effects on uterine growthSteroids, 1973
- Mechanism of Action of the Female Sex HormonesAnnual Review of Biochemistry, 1972
- Formation of estrogen nuclear receptor in uterus: Effect of androgens, estrone and nafoxidineBiochemical and Biophysical Research Communications, 1972
- A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474British Journal of Cancer, 1971
- Anti-oestrogens and breast cancerEuropean Journal of Cancer (1965), 1971
- Inhibition of DMBA-Induced Mammary Carcinogenesis in the Rat by 2-Br-α-Ergocryptine (CB 154), An Inhibitor of Prolactin Secretion, and by Nafoxidine (U-11, 100 A), an Estrogen AntagonistGynecologic and Obstetric Investigation, 1971